Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel
Purpose The pregnancy cohort was established to examine the prevalence and variety of haemoglobinopathies in a high-risk group of pregnant women.Participants The pregnancy cohort is located in the Department of Obstetrics and Antenatal Care, University Hospital of Basel. The pregnant women were recr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/7/e035735.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139100534800384 |
|---|---|
| author | Gabriela Amstad Bencaiova Irene Hoesli Franziska Geissler |
| author_facet | Gabriela Amstad Bencaiova Irene Hoesli Franziska Geissler |
| author_sort | Gabriela Amstad Bencaiova |
| collection | DOAJ |
| description | Purpose The pregnancy cohort was established to examine the prevalence and variety of haemoglobinopathies in a high-risk group of pregnant women.Participants The pregnancy cohort is located in the Department of Obstetrics and Antenatal Care, University Hospital of Basel. The pregnant women were recruited in the first trimester between June 2015 and May 2019. Family origin questionnaires were used to screen pregnant women for the risk of a haemoglobin variant. Based on the questionnaire, pregnant women were divided into two groups: women with a high risk and women with a low risk of a haemoglobin variant. In women with a high risk, red blood cell indices, iron status and chromatography were conducted.Findings to date 1785 pregnant women were recruited. Out of the 1785 women, 929 were identified as a part of the high-risk group. Due to the missing data of 74 pregnant women with a high risk, the final analysis was conducted in the remaining 855 women. The prevalence of haemoglobinopathies in the high-risk group was 14.5% (124/855).Future plans This cohort will be used to: (1) implement the screening in prenatal care in Basel; (2) recommend the screening among pregnant women with a high risk of a haemoglobin variant in Switzerland; (3) improve prenatal and neonatal care in patients with a haemoglobin variant; (4) examine adverse pregnancy outcomes in women with a haemoglobin variant and (5) reduce maternal and neonatal morbidity and mortality in the future.Trial registration number ClinicalTrials.gov Registry (NCT04029142). |
| format | Article |
| id | doaj-art-8759496fd7314158a4791c131afd2c20 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-8759496fd7314158a4791c131afd2c202025-08-20T02:30:24ZengBMJ Publishing GroupBMJ Open2044-60552020-07-0110710.1136/bmjopen-2019-035735Cohort profile: targeted antenatal screening for haemoglobinopathies in BaselGabriela Amstad Bencaiova0Irene Hoesli1Franziska Geissler2Department of Obtetrics and Antenatal Care, University Hospital Basel, Basel, SwitzerlandDepartment of Obstetrics and Gynaecology, University Hospital Basel, Basel, Switzerland46 Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, Basel, SwitzerlandPurpose The pregnancy cohort was established to examine the prevalence and variety of haemoglobinopathies in a high-risk group of pregnant women.Participants The pregnancy cohort is located in the Department of Obstetrics and Antenatal Care, University Hospital of Basel. The pregnant women were recruited in the first trimester between June 2015 and May 2019. Family origin questionnaires were used to screen pregnant women for the risk of a haemoglobin variant. Based on the questionnaire, pregnant women were divided into two groups: women with a high risk and women with a low risk of a haemoglobin variant. In women with a high risk, red blood cell indices, iron status and chromatography were conducted.Findings to date 1785 pregnant women were recruited. Out of the 1785 women, 929 were identified as a part of the high-risk group. Due to the missing data of 74 pregnant women with a high risk, the final analysis was conducted in the remaining 855 women. The prevalence of haemoglobinopathies in the high-risk group was 14.5% (124/855).Future plans This cohort will be used to: (1) implement the screening in prenatal care in Basel; (2) recommend the screening among pregnant women with a high risk of a haemoglobin variant in Switzerland; (3) improve prenatal and neonatal care in patients with a haemoglobin variant; (4) examine adverse pregnancy outcomes in women with a haemoglobin variant and (5) reduce maternal and neonatal morbidity and mortality in the future.Trial registration number ClinicalTrials.gov Registry (NCT04029142).https://bmjopen.bmj.com/content/10/7/e035735.full |
| spellingShingle | Gabriela Amstad Bencaiova Irene Hoesli Franziska Geissler Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel BMJ Open |
| title | Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel |
| title_full | Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel |
| title_fullStr | Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel |
| title_full_unstemmed | Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel |
| title_short | Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel |
| title_sort | cohort profile targeted antenatal screening for haemoglobinopathies in basel |
| url | https://bmjopen.bmj.com/content/10/7/e035735.full |
| work_keys_str_mv | AT gabrielaamstadbencaiova cohortprofiletargetedantenatalscreeningforhaemoglobinopathiesinbasel AT irenehoesli cohortprofiletargetedantenatalscreeningforhaemoglobinopathiesinbasel AT franziskageissler cohortprofiletargetedantenatalscreeningforhaemoglobinopathiesinbasel |